No. of Pages: 169 | Report Code: TIPRE00027987 | Category: Life Sciences
Â
북미 지역 시장의 유리한 정부 규제로 인해 팬데믹이 시작되는 동안 단일클론 항체가 승인됩니다. 예를 들어, 2021년 12월 미국 식품의약국(FDA)은 코로나19의 노출 전 예방을 위한 AstraZeneca의 Evusheld(tilgavimab과 함께 포장되어 함께 투여되는 tixagevimab)에 대한 긴급 사용 승인(EUA)을 발표했습니다. 특정 성인 및 소아 개인의 경우. 단일클론 항체는 바이러스와 같은 유해한 병원체와 싸우는 면역 체계의 능력을 모방하는 데 관여하는 실험실에서 제조된 단백질입니다. 따라서 \"Tixagevimab\"과 \"cilgavimab\"은 특히 SARS-CoV-2의 스파이크 단백질에 대한 지속성 단일클론 항체입니다. 그 외에도, 생물학적 제제 개발을 위한 유리한 자금 지원은 북미 지역 시장에서 대유행이 시작되는 동안 단클론 항체의 시장 성장을 더욱 강화했습니다. 예를 들어, 미국 국제개발금융공사(DFC)는 코로나19 백신 제조 용량을 늘리기 위해 Biological E Limited에 5천만 달러를 제공한다고 발표했습니다. 또한 FDA의 생물의약품 제품 승인과 관련된 유리한 정책은 시장 성장에 긍정적인 영향을 미칩니다.Â
공급업체는 새로운 기능과 기술을 통해 새로운 고객을 유치할 수 있습니다. 신흥 시장에서 입지를 확장합니다. 이 요인은 단일클론 항체 시장을 주도할 가능성이 높습니다. 북미 단클론 항체 시장은 예측 기간 동안 양호한 CAGR로 성장할 것으로 예상됩니다.Strategic insights for North America Monoclonal Antibodies involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 54,629.4 Million |
| Market Size by 2028 | US$ 1,20,713.2 Million |
| Global CAGR (2021 - 2028) | 12.0% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By 출처
|
| Regions and Countries Covered | 북미
|
| Market leaders and key company profiles |
The regional scope of North America Monoclonal Antibodies refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The North America Monoclonal Antibodies Market is valued at US$ 54,629.4 Million in 2021, it is projected to reach US$ 1,20,713.2 Million by 2028.
As per our report North America Monoclonal Antibodies Market, the market size is valued at US$ 54,629.4 Million in 2021, projecting it to reach US$ 1,20,713.2 Million by 2028. This translates to a CAGR of approximately 12.0% during the forecast period.
The North America Monoclonal Antibodies Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Monoclonal Antibodies Market report:
The North America Monoclonal Antibodies Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Monoclonal Antibodies Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Monoclonal Antibodies Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Monoclonal Antibodies Market
